Heart failure (HF) is now one of the fastest growing cardiovascular conditions in the world. In Canada, it’s estimated that more than 100,000 Canadians will be diagnosed this year alone, adding to the 750,000 people already living with HF.
In response to this growing trend, the Canadian Heart Failure Society (CHFS), together with partner organizations, will be hosting the 6th annual national Heart Failure Awareness Week campaign taking place May 5-11, 2024.
The goal of Heart Failure Awareness Week is to raise awareness, increase public knowledge and provide a better understanding about this chronic condition.
CHFS is proud to collaborate with the following organizations in providing tools and helpful resources for the general public, for healthcare providers and for people living with heart failure:
- Canadian Cardiovascular Society (CCS)
- Canadian Council of Cardiovascular Nurses (CCCN)
- Canadian Association of Cardiovascular Prevention and Rehabilitation (CACPR)
- Canadian Heart Function (CHF) Alliance
- Heart & Stroke
- HeartLife Foundation
- Ted Rogers Centre for Heart Research
PLEASE JOIN US IN RAISING AWARENESS!
Tools and Resources
Our updated 2024 tools and resources will be available soon so please check back!
In the meantime, please feel free to access the 2023 Poster, Patient Handout, and Event Planning Kit still available for download. Other resources are also available below websites.
Event Planning Kit
- Event Guide: How to plan your own event
- Presentation slides: Heart Failure - Incidence, Prevalence & Risk Factors
- Sample invitation
- Sample evaluation form
Social Media Tools
Presented by Heart & Stroke and HeartLife Foundation
It’s Not Normal to be Breathless - Know the Signs and Symptoms of Heart Failure: Act Now and Live Longer
Where to find Heart Failure Resources
Patient Education and Support Resources
Professional Education Resources
Follow us @CanHFSociety on Twitter and #HeartFailureWeekCan.
This event is made possible through the support from Abbott, AstraZeneca, Bayer Inc., Boehringer Ingelheim-Lilly, Novartis, Pfizer Canada and Servier.